# Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

> **NCT05491616** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 77 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05491616
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-29
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491616, "Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05491616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*